EU says second Chinese firm’s heart drug is possibly carcinogenic
There could be one extra case of cancer for every 5,000 patients who took the tainted valsartan made by Zhejiang Huahai, based on taking the highest dose every day for seven years
Frankfurt — The European Medicines Agency (EMA) said on Friday that a second Chinese contract manufacturer, Zhejiang Tianyu, had produced a common blood pressure and heart drug with an impurity that could cause cancer. The alarm over the valsartan drug was first raised in July, prompting a global recall of affected pills. The EMA initially said the problem probably dated back to changes in manufacturing processes at Zhejiang Huahai Pharmaceutical in 2012. But N-nitrosodimethylamine, a probable human carcinogen, was also found in batches of valsartan made by Zhejiang Tianyu, although at much lower levels than in the case of Zhejiang Huahai, the EMA said in a statement. "EMA is working closely with international partners to review the impact of the NDMA detected in valsartan from Zhejiang Tianyu and will communicate as soon as additional information becomes available," the regulator said. The EMA has said there could be one extra case of cancer for every 5,000 patients that had taken ...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.